Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index falling 2.1% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 2.3%.
In corporate news, NeOnc Technologies (NTHI) said the US Food and Drug Administration rescheduled its end-of-phase 1 type B meeting for oral cancer drug NEO212 to Monday from Nov. 17. The meeting's scheduling "does not establish FDA agreement on a trial design or eventual approval of NEO212," the company said Thursday in a statement. Its shares fell 20%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.